Patent for Sale:

ST104P, an Anti-angiogenesis Agent    

A tetrameric cyclic compound,perturbs migration and formation of endothelial cells, abolishes neovascularization, delays tumor growth.

Overview

ST104P is a totally synthesized compound. It is easy to synthesize, stable, and highly water soluble. It can be formulated into oral dosage form, eye drop form for topical and periocular application and injectable form.
ST104P is able to block the angiogenic activity of bFGF when they are co-implanted into rat cornea.
ST104P is also able to inhibit the angiogenic activity of implanted bFGF when it is applied topically as eye drops.
ST104P is able to block the pathological changes of the bFGF implant when it is applied as eye drop.
ST104P is able to inhibit choroidal neovascularization induced by laser when administered by intravitreal injection in rat.

Primary Application of the Technology

Coneal implant rejection by neovascularization, age-related muscular degeneration, angiogenesis predominant cancer, cancer metastasis

Other Potential Applications

Excessive angiogenesis related disorder.
Can be formulated into oral dosage form, eye drop form for topical and periocular application.

The Problem Solved by the Technology

Avastin (Bevacizumab), an anti-angiogenesis agent approved by FDA is a humanized monoclonal antibody against VEGF for the first line treatment of metastatic colorectal cancer. Its Fab fragment, Lucentis, is approved by FDA for age-related macular degeneration and macular edema following retinal vein occlusion. Protein drug has its limitation because it is very difficult and expensive to manufacture, limited stability, specified condition for storage and shipping , most importantly, injection administration route (Lucentis is applied by intravitreal injection).

Competitive Advantage

ST104P is a totally synthesized compound. It is easy to synthesize, stable, and highly water soluble. It can be formulated into oral dosage form, eye drop form for topical and periocular application and injectable form.
ST104P is able to block the angiogenic activity of bFGF when they are co-implanted into rat cornea.
ST104P is also able to inhibit the angiogenic activity of implanted bFGF when it is applied topically as eye drops.
ST104P is able to block the pathological changes of the bFGF implant when it is applied as eye drop.
ST104P is able to inhibit choroidal neovascularization induced by laser when administered by intravitreal injection in rat.

The seller may consider selling these patents individually.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 514: Drug, Bio-Affecting And Body Treating Compositions

This class is an integral part of Class 424. It includes the following subject matter, not provided for elsewhere: 1. Drug and bio-affecting compositions which are capable of: preventing, alleviating, treating, or curing abnormal and pathological conditions of the living body; maintaining, increasing, decreasing, limiting, or destroying a physiologic body function; diagnosing a physiological condition or state by an in vivo test; controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or micro-organism. 2. Body treating compositions generally intended for deodorizing, protecting, adorning, or grooming a body. 3. Fermentates. Plant and animal extracts, or body fluids or material containing plant or animal cellular structure. 4. Compositions of this class defined in terms of specific structure; e.g., layered tablet, capsule. 5. Processes of using or preparing subject matter of the Class Definition.

Subclass 732: Polycyclo ring system (e.g., naphthols, etc.)